Market Cap 10.29B
Revenue (ttm) 12.82B
Net Income (ttm) 936.34M
EPS (ttm) N/A
PE Ratio 14.54
Forward PE 12.73
Profit Margin 7.31%
Debt to Equity Ratio -1,501.73
Volume 733,800
Avg Vol 837,226
Day's Range N/A - N/A
Shares Out 75.50M
Stochastic %K 88%
Beta 1.11
Analysts Sell
Price Target $162.28

Company Profile

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative se...

Industry: Medical Care Facilities
Sector: Healthcare
Phone: 720-631-2100
Address:
2000 16th Street, Denver, United States
SparkyReturns
SparkyReturns Jun. 24 at 3:33 PM
$TAK Something to look at. Small cap investing idea: ICU recently beat down from a capital raise a few days ago, which was just reported will make them Nasdaq compliant. Waiting on confirmation. ICU has a unique SCD device which treats Acute Kidney Infection and has also been approved for compassionate and emergency use for Sepsis. FDA loves it so much has granted multiple breakthrough device designations, and has even awarded grants. Also Dept of Defense money to study use in burn or trauma cases. The device can calm the cytokine storm which can happen in a variety of conditions from AKI to sepsis to heart attacks to burn cases, Covid, etc. TAM in the tens of Billions. Current market cap approx. 8M. Read that again. Let that sink in. Reversal incoming. Cheers! $SYK $DVA $FMS
0 · Reply
IntensiveCareUnit
IntensiveCareUnit Jun. 23 at 6:26 PM
$ICU I just think we're sleeping on buyout instead of commercial ramp up if IA goes well in august. Fresenius $FMS and DaVita $DVA make so much money every quarter, why would they not want to control a product that directly impacts their main product of dialysis? Fresenius already knows about it, they manufacture the product. Why not bring it all in house? It'd be chump change for them.
1 · Reply
Ryant19
Ryant19 Jun. 23 at 3:26 PM
$CRMD Too bad $DVA is in bed with $ICUI. Turning a blind eye to patient safety due to back room deals
1 · Reply
Thewonderyears
Thewonderyears Jun. 16 at 8:56 AM
$DVA Government Contract Update: $206M payment to DAVITA INC
0 · Reply
DonCorleone77
DonCorleone77 May. 30 at 8:05 PM
$DVA DaVita 'applauds' CMMI decision to extend Kidney Care Choices Model DaVita issued the following statement in response to updates this week from the Center for Medicare and Medicaid Innovation related to its Kidney Care Choices Model. Misha Palecek, Chief Transformation Officer for DaVita, said: "As a dedicated participant in the government's value-based care initiative and a pioneer in this field for the last twenty years, we applaud CMMI's decision to extend the Kidney Care Choices Model for an additional year. We believe the investments made by CMMI and participants alike will result in long-term savings in the upcoming years. The program's emphasis on comprehensive, collaborative care and patient engagement is driving encouraging health outcomes. DaVita is committed to establishing a new standard for kidney care through integrated care systems alongside our nephrology partners."
0 · Reply
Mallingan
Mallingan May. 29 at 12:38 PM
0 · Reply
AlertsAndNews
AlertsAndNews May. 28 at 2:53 AM
$DVA $BRK.A $BRK.B DaVita Buffett selling some. Warren E. Buffett (10%+ owner) sells 200,000 shares at an average price of $138.85. Still has 33M+ shares.
0 · Reply
Mallingan
Mallingan May. 26 at 10:41 AM
$DVA https://www.ibtimes.co.uk/warren-buffett-sells-168m-davita-shares-one-day-before-dialysis-provider-hit-lawsuit-1733814
0 · Reply
Mallingan
Mallingan May. 24 at 12:29 PM
$DVA https://www.reuters.com/legal/government/dialysis-giants-davita-fresenius-medical-sued-by-employee-benefits-plan-2025-05-12/
0 · Reply
FuckThisTrade
FuckThisTrade May. 22 at 7:56 PM
$DVA is undervalued. Intrinsic Value Estimates: Alpha Spread calculates DaVita’s intrinsic value at approximately $245.17, suggesting the stock is undervalued by about 43% compared to its current market price of $138.74 .  • Discounted Cash Flow (DCF) Analysis: Simply Wall St estimates a fair value of $271.71 per share, indicating the stock is trading at a 48% discount .  • Price-to-Earnings (P/E) Ratio: DaVita’s current P/E ratio is 14.35, which is below its 12-month average of 15.68 and significantly lower than the healthcare industry average of 24.17 . 
0 · Reply
Latest News on DVA
DaVita: International Expansion And Buybacks Will Boost Returns

May 27, 2025, 11:30 AM EDT - 4 weeks ago

DaVita: International Expansion And Buybacks Will Boost Returns


DaVita Inc. Announces Offering of $750 Million Senior Notes

May 20, 2025, 8:51 AM EDT - 5 weeks ago

DaVita Inc. Announces Offering of $750 Million Senior Notes


DaVita Inc. (DVA) Q1 2025 Earnings Call Transcript

May 12, 2025, 9:41 PM EDT - 6 weeks ago

DaVita Inc. (DVA) Q1 2025 Earnings Call Transcript


DaVita First-Quarter 2025 Financial Results: Just the Numbers

May 12, 2025, 4:51 PM EDT - 6 weeks ago

DaVita First-Quarter 2025 Financial Results: Just the Numbers


DaVita Inc. 1st Quarter 2025 Results

May 12, 2025, 4:05 PM EDT - 6 weeks ago

DaVita Inc. 1st Quarter 2025 Results


DaVita Inc. Schedules 1st Quarter 2025 Investor Conference Call

Apr 30, 2025, 11:00 AM EDT - 7 weeks ago

DaVita Inc. Schedules 1st Quarter 2025 Investor Conference Call


DaVita Says Ransomware Attack Affecting Some Operations

Apr 14, 2025, 7:35 AM EDT - 2 months ago

DaVita Says Ransomware Attack Affecting Some Operations


Dialysis firm DaVita hit by ransomware attack

Apr 14, 2025, 7:33 AM EDT - 2 months ago

Dialysis firm DaVita hit by ransomware attack


Berkshire Hathaway sells another 750,000 DaVita shares

Feb 19, 2025, 8:05 PM EST - 4 months ago

Berkshire Hathaway sells another 750,000 DaVita shares


DaVita Inc. (DVA) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 8:19 PM EST - 4 months ago

DaVita Inc. (DVA) Q4 2024 Earnings Call Transcript


Berkshire sells some DaVita shares, cuts stake to 45%

Feb 13, 2025, 8:13 PM EST - 4 months ago

Berkshire sells some DaVita shares, cuts stake to 45%


DaVita forecasts 2025 profit below estimates, shares plummet

Feb 13, 2025, 6:07 PM EST - 4 months ago

DaVita forecasts 2025 profit below estimates, shares plummet


DaVita Inc. 4th Quarter 2024 Results

Feb 13, 2025, 4:05 PM EST - 4 months ago

DaVita Inc. 4th Quarter 2024 Results


DaVita Inc. Schedules 4th Quarter 2024 Investor Conference Call

Jan 30, 2025, 11:55 AM EST - 5 months ago

DaVita Inc. Schedules 4th Quarter 2024 Investor Conference Call


DaVita Inc. (DVA) Q3 2024 Earnings Call Transcript

Oct 29, 2024, 9:27 PM EDT - 8 months ago

DaVita Inc. (DVA) Q3 2024 Earnings Call Transcript


DaVita misses third-quarter profit estimates on higher costs

Oct 29, 2024, 4:23 PM EDT - 8 months ago

DaVita misses third-quarter profit estimates on higher costs


DaVita Inc. 3rd Quarter 2024 Results

Oct 29, 2024, 4:05 PM EDT - 8 months ago

DaVita Inc. 3rd Quarter 2024 Results


DaVita Appoints Jessica Hergenreter as Chief People Officer

Oct 17, 2024, 1:00 PM EDT - 8 months ago

DaVita Appoints Jessica Hergenreter as Chief People Officer


DaVita Inc. Schedules 3rd Quarter 2024 Investor Conference Call

Oct 9, 2024, 1:47 PM EDT - 9 months ago

DaVita Inc. Schedules 3rd Quarter 2024 Investor Conference Call


Drop Johnson & Johnson, Pick These Steady Eddie Stocks?

Aug 30, 2024, 8:00 AM EDT - 10 months ago

Drop Johnson & Johnson, Pick These Steady Eddie Stocks?

DUK JNJ


DaVita Inc. Announces Offering of $1.0 Billion Senior Notes

Aug 8, 2024, 9:16 AM EDT - 11 months ago

DaVita Inc. Announces Offering of $1.0 Billion Senior Notes


DaVita Inc. 2nd Quarter 2024 Results

Aug 6, 2024, 4:05 PM EDT - 11 months ago

DaVita Inc. 2nd Quarter 2024 Results


SparkyReturns
SparkyReturns Jun. 24 at 3:33 PM
$TAK Something to look at. Small cap investing idea: ICU recently beat down from a capital raise a few days ago, which was just reported will make them Nasdaq compliant. Waiting on confirmation. ICU has a unique SCD device which treats Acute Kidney Infection and has also been approved for compassionate and emergency use for Sepsis. FDA loves it so much has granted multiple breakthrough device designations, and has even awarded grants. Also Dept of Defense money to study use in burn or trauma cases. The device can calm the cytokine storm which can happen in a variety of conditions from AKI to sepsis to heart attacks to burn cases, Covid, etc. TAM in the tens of Billions. Current market cap approx. 8M. Read that again. Let that sink in. Reversal incoming. Cheers! $SYK $DVA $FMS
0 · Reply
IntensiveCareUnit
IntensiveCareUnit Jun. 23 at 6:26 PM
$ICU I just think we're sleeping on buyout instead of commercial ramp up if IA goes well in august. Fresenius $FMS and DaVita $DVA make so much money every quarter, why would they not want to control a product that directly impacts their main product of dialysis? Fresenius already knows about it, they manufacture the product. Why not bring it all in house? It'd be chump change for them.
1 · Reply
Ryant19
Ryant19 Jun. 23 at 3:26 PM
$CRMD Too bad $DVA is in bed with $ICUI. Turning a blind eye to patient safety due to back room deals
1 · Reply
Thewonderyears
Thewonderyears Jun. 16 at 8:56 AM
$DVA Government Contract Update: $206M payment to DAVITA INC
0 · Reply
DonCorleone77
DonCorleone77 May. 30 at 8:05 PM
$DVA DaVita 'applauds' CMMI decision to extend Kidney Care Choices Model DaVita issued the following statement in response to updates this week from the Center for Medicare and Medicaid Innovation related to its Kidney Care Choices Model. Misha Palecek, Chief Transformation Officer for DaVita, said: "As a dedicated participant in the government's value-based care initiative and a pioneer in this field for the last twenty years, we applaud CMMI's decision to extend the Kidney Care Choices Model for an additional year. We believe the investments made by CMMI and participants alike will result in long-term savings in the upcoming years. The program's emphasis on comprehensive, collaborative care and patient engagement is driving encouraging health outcomes. DaVita is committed to establishing a new standard for kidney care through integrated care systems alongside our nephrology partners."
0 · Reply
Mallingan
Mallingan May. 29 at 12:38 PM
0 · Reply
AlertsAndNews
AlertsAndNews May. 28 at 2:53 AM
$DVA $BRK.A $BRK.B DaVita Buffett selling some. Warren E. Buffett (10%+ owner) sells 200,000 shares at an average price of $138.85. Still has 33M+ shares.
0 · Reply
Mallingan
Mallingan May. 26 at 10:41 AM
$DVA https://www.ibtimes.co.uk/warren-buffett-sells-168m-davita-shares-one-day-before-dialysis-provider-hit-lawsuit-1733814
0 · Reply
Mallingan
Mallingan May. 24 at 12:29 PM
$DVA https://www.reuters.com/legal/government/dialysis-giants-davita-fresenius-medical-sued-by-employee-benefits-plan-2025-05-12/
0 · Reply
FuckThisTrade
FuckThisTrade May. 22 at 7:56 PM
$DVA is undervalued. Intrinsic Value Estimates: Alpha Spread calculates DaVita’s intrinsic value at approximately $245.17, suggesting the stock is undervalued by about 43% compared to its current market price of $138.74 .  • Discounted Cash Flow (DCF) Analysis: Simply Wall St estimates a fair value of $271.71 per share, indicating the stock is trading at a 48% discount .  • Price-to-Earnings (P/E) Ratio: DaVita’s current P/E ratio is 14.35, which is below its 12-month average of 15.68 and significantly lower than the healthcare industry average of 24.17 . 
0 · Reply
bullishbaer
bullishbaer May. 20 at 9:38 PM
$DVA I wanted to share a quick update on a significant move we’ve made that reflects the strength and strategic direction of our company. We recently up-sized and priced our previously announced private offering increasing it to $1.75 billion in aggregate principal amount of senior notes due 2032. The notes will carry a 5.000% annual interest rate, paid semi-annually. The strong investor interest that allowed us to up-size this offering speaks volumes about confidence in our long-term vision. Proceeds will primarily go toward refinancing our 4.625% senior notes due 2030 and supporting overall corporate initiatives. From inside the company, I can tell you there’s a lot of energy around the thoughtful way we're managing our capital structure to support future growth and operational resilience.
0 · Reply
CHItraders
CHItraders May. 20 at 8:44 PM
$DVA DaVita Announces Upsize And Pricing Of Its Previously Announced Private Offering Of Its 6.750% Senior Notes Due 2033 From $750M To $1B
0 · Reply
JarvisFlow
JarvisFlow May. 19 at 1:15 PM
Truist Securities has adjusted their stance on DaVita ( $DVA ), setting the rating to Hold with a target price of 170 → 164.
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 May. 13 at 9:49 PM
$DVA LMAO They won’t reveal how bad the business is doing. They will keep buying its own stock, spending all free cash and then some. This will end really badly. JMO
1 · Reply
Bazzzigar
Bazzzigar May. 13 at 9:42 PM
$DVA Sold...Moved to UNH
0 · Reply
ballzdeep12
ballzdeep12 May. 13 at 3:01 PM
$DVA easy money. This shit always goes back to above 140
0 · Reply
Gecko1987
Gecko1987 May. 13 at 2:08 PM
$DVA curious if anyone listened to this advice?
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 May. 13 at 1:38 PM
$DVA Tanking as expected.
1 · Reply
profit_guru
profit_guru May. 13 at 1:28 PM
$DVA - they have consistent share buybacks…must be trading above 160…imo
0 · Reply
Huck18
Huck18 May. 12 at 9:02 PM
$DVA Symbols, Analysts, Keywords Entering text into the input field will update the search result below Entering text into the input field will update the search result below DaVita Non-GAAP EPS of $2.00 misses by $0.02, revenue of $3.22B beats by $10M May 12, 2025 4:16 PM ETDaVita Inc. (DVA) StockBy: Urvi Shah, SA News Editor Play (<1min) DaVita press release (NYSE:DVA): Q1 Non-GAAP EPS of $2.00 misses by $0.02. Revenue of $3.22B (+4.9% Y/Y) beats by $10M. Operating cash flow was $180 million and free cash flow was $(45) million. Repurchased 3.7 million shares of the Company's common stock at an average price paid of $148.94 per share. Financial and operating metrics: Three months ended March 31, Twelve months ended March 31, 2025 2024 2025 2024 Cash flow: (dollars in millions) Operating cash flow $ 180 $ (135) $ 2,337 $ 1,462 Free cash flow(1) $ (45) $ (327) $ 1,444 $ 645
0 · Reply
JADED_BULL
JADED_BULL May. 12 at 8:28 PM
$DVA option sellers be like
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 May. 12 at 8:27 PM
$DVA Don’t get fooled by the fake “adjusted” EPS. The free cashflow is negative, profit net margin decreased by full 200 basis points, and real income is down 65% from last year. This is dying. $120-110 tomorrow. JMO
0 · Reply